Academic literature on the topic 'Dexametazone'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dexametazone.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dexametazone"

1

Peshev, Raiko, Ivo Sirakov, Nedelcho Nedelchev, and Stoil Karadzhov. "ETIOLOGICAL AND MOLECULAR BIOLOGICAL INVESTIGATION OF CAPRINE HERPESVIRUS 1 ISOLATED IN BULGARIA." Archives of Veterinary Medicine 2, no. 2 (2009): 27–38. http://dx.doi.org/10.46784/e-avm.v2i2.216.

Full text
Abstract:
From goat and bucks with genital disorders and abortions the attempts for isolation of caprine herpesvirus 1 (CHV 1) were carried out. For virus exaltation Dexametazone was used. For viruses isolation vaginal, nasal, rectal, preputial swabs and organ samples were used. Primary and continuous cell cultures rabbit kidney (RK), Madin Darby bovine kidney (MDBK), and embrional bovine trachea (EBTR) were used for cultivation. For determination of DNA type and lipid envelop 60 μg/ml iod desoxiuridine (JDUR) and the ether treat ment was used. Neutralization by specific hyperimmune serum obtained from Switzerland was performed. Five CHV 1 strains were isolated by cell cultures and identified as goat herpesviruses from dif ferent Bulgarian regions. After electron microscopy the viral agents with typical size and morphology for herpesviruses were established. For demonstration gC gene of CHV 1 the polymerase chain reaction (PCR) with primers designed from sequences deposited in gene bank were developed. Isolated on cell cultures herpesviruses were proved as caprine herpesvirus 1 by using applied PCR variant. The products after gC gene amplification from Bulgarian isolates were separated on the same place as the amplicons of ref er ence CHV 1 strains.
APA, Harvard, Vancouver, ISO, and other styles
2

Hryhorieva, Olena A., Arthur V. Chernyavskiy, and Yuriy Yo Guminskiy. "MORPHOLOGICAL FEATURES OF RATS’ HEARTS AFTER INTRAFETAL INJECTION OF DEXAMETHASONE." Wiadomości Lekarskie 74, no. 2 (2021): 247–51. http://dx.doi.org/10.36740/wlek202102113.

Full text
Abstract:
The aim: Is to study the morphological features of rats’ hearts after prenatal administration of glucocorticoids. Materials and methods: In this study we used histological, immunohistochemical, electron-microscopic and statistical research methods. Results: It is found that at 30th day after birth in rats after intrafetal introduction of dexamethasone in myocardium a relative area occupied by arterial vessels is significantly smaller in comparison with control. Absolute and relative number of Ki-67+-cardiomyocytes in the myocardium of experimental rats is reduced throughout the second week after birth and is significantly less compared to the control group. In the nuclei of cardiomyocytes of experimental rats is rendered the greater amount of heterochromatin in comparison with cardiomyocytes of the control group where euchromatin prevails. Conclusions: After intrafetal injection of dexametazone changes in dynamics and significantly smaller index of relative area occupied by arterial vessels in ventricular myocardium at the 30th day after birth are observed; the absolute and relative number of Ki-67+ -cardiomyocytes in myocardium decreases during the second week after birth and is significantly lower compared to the control group; in the nuclei of cardiomyocytes of experimental rats a greater amount of heterochromatin is visualized, and in cardiomyocytes of the control group – euchromatin.
APA, Harvard, Vancouver, ISO, and other styles
3

Masárová, Katarína, Zdenka Stefanikova, Martin Mistrik, and Angelika Batorova. "Effectiveness of Lenalidomide and Dexamethasone for the Treatment of Extramedullary Plasmacytoma in Patients with Multiple Myeloma: Report of Two Cases." Blood 124, no. 21 (2014): 5760. http://dx.doi.org/10.1182/blood.v124.21.5760.5760.

Full text
Abstract:
Abstract Extramedullary plasmacytoma (EMP) can occur at the time of primary diagnosis of multiple myeloma (MM), during the disease, or as solitary plasmacytoma without bone marrow involvement. The presence of EMP at any time in the course of disease is associated with significantly shorter overall survival and progression-free survival. We report a series of two patients with EMP who were successfully treated with lenalidomide and dexamethasone. The first patient was diagnosed in 2006 with EMP in the spine without presence of MM at the time of diagnosis. Reconstruction surgery followed by high dose dexamethasone treatment led to stabilization of patient’s condition. Patient received zoledronic acid for prevention of skeletal fractures. In 2011 the patient was diagnosed with MM and two new EMP lesions in the spine were discovered. The patient received bortezomib and achieved a partial remission. In 2012 a significant growth of EMP in retroperitoneum was observed. Tumor was surgically removed, plasmacytoma was confirmed histologically. Patient was treated with lenalidomide and dexamethasone with subsequent autologous peripheral blood stem cell transplantation (APBSCT) and achieved complete remission. Patient Two had advanced stage of MM at the time of diagnosis, without presence of EMP. She was treated with induction therapy followed by APBSCT. EMP in the area of clivus, diagnosed three years after initial diagnosis of MM was successfully managed with conventional chemotherapy and radiotherapy. In 2010 another EMP in the left sphenoid sinus progressed during relapse of MM. Treatment with lenalidomide and dexametazone led to remission of MM and disparition of EMP. Both patients are in complete remission at the time of submitting this abstract. Our clinical experience strongly suggests that lenalidomide with dexamethasone is an effective agent for treating EMP in patients with MM. The treatment was well tolerated with manageable side effects. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
4

SCHNITZLER, Egon, Marco Aurélio da Silva CARVALHO-FILHO, Carlos Cezar STADLER, Ana Márcia VOLPATO, and Massao IONASHIRO. "Aplicação da calorimetria exploratória diferencial (dsc) na caracterização térmica do acetato de dexametazona, excipientes e do creme de dexametazona." Eclética Química 26 (2001): 41–52. http://dx.doi.org/10.1590/s0100-46702001000100003.

Full text
Abstract:
A calorimetria exploratória diferencial (DSC) foi utilizada na caracterização do acetato de dexametazona (princípio ativo), álcool cetílico, emulgin, polawax, nipagim-M (excipientes). O princípio ativo também foi investigado utilizando-se a termogravimetria (TG) e espectroscopia de absorção na região do ultravioleta e visível (UV-VIS). Os resultados obtidos permitiram verificar a estabilidade térmica e o ponto de fusão do princípio ativo, bem como o ponto de fusão dos excipientes utilizados na fabricação do creme de dexametazona.
APA, Harvard, Vancouver, ISO, and other styles
5

Rupolo, M., M. Michieli, M. Spina, et al. "R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 8036. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8036.

Full text
Abstract:
8036 Second line regimens in NHL are mainly based on cisplatin (DDP). The substitution of DDP with oxaliplatin in DHAP- like regimens may result in lower toxicity and higher activity. In R/R CD20+ follicular (F) and mantle cell (MC) NHL the sinergistic activity of rituximab with chemotherapy and the maintenance immunotherapy obtain and prolong clinical and molecular remission. We assessed the tolerability and the activity in terms of clinical and molecular remission of R-Dhaox (rituximab 375 mg/m2 i.v., day 1, dexametazone 40 mg i.v. days 1–4, Oxaliplatin 130 mg/m2, day 2 and cytarabine 2,000 mg/m2 i.v. twice a day day 3) regimen for 4 courses in phase II study. The pts in response underwent to HDC with the scheme BEAM-R and further were treated with maintenance therapy with rituximab 375 mg/m2 i.v. 75+ from ABMT. After three monthly doses, pts were treated with further five every 4 months (for a total of two years). From June 2002 to September 2006, 31 pts were enrolled. 19 were male and 12 female. Median age was 51 (30–66). 21 (68%) pts were follicular G1-G2, 9 (29%) mantle cells and 1 a transformed follicular. The stage was III for 8 (26%) and IV for 23 (74%) pts. 22 (70%) pts were previous treated with rituximab and 30 (96%) with adryamicin based schedules. CD34+ harvest was after 4th cycle with a median collection of 5,5 ×106/Kg (2,1–20); 2 were positive for BCL-2 and 1 for BCL-1. Overall clinical response before ABMT was 94% for F and 100% for MC. 26 pts underwent ABMT with the schedule BEAM-R. At relapse 54% (12/22) of F were BCL-2 positive and 66% (6/9) of MC for BCL-1. Before ABMT 4/17 pts were BCL-2 positive and 1/9 for BCL-1. Among F, 3 pts relapsed after ABMT: 2 with reexpression of BCL-2 and 1 without. No relapse among MC, all negative for BCL-1 after ABMT. No pt showed severe or fatal infections during maintenance immunotherapy. Three- year projected free survival was 100% for MC and 68% for F NHL. These preliminary data suggested that R-DHAOX, HDC and rituximab maintenance is a novel approach highly effective for R/R F and MC NHL. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
6

Curreli, L., A. D. Palmas, G. Latte, A. Murgia, and A. Gabbas. "Avascular necrosis of the jaw in multiple myeloma (MM) patients (pts) treated with bisphosphonates (BP)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18538. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18538.

Full text
Abstract:
18538 Background: Oral cavity avascular bone necrosis (ABN) has been recently reported as an emerging serious complication in pts receiving BP for the treatment of hypercalcemia related to MM or metastatic solid tumors. Methods: We report the cases of 6 pts with MM treated initially with pamidronate and later with zoledronic acid (ZA). Results: Pts characteristics : M/F 3/3; mean age 58.4 (46–78); 4 IgG κ,1 γ and 1 κ MM; 5 St IIIA and 1 IIIB; mean history of disease 61.3 mo. (23–103); 5 pts had a relapsing MM refractory to several lines of therapy but 1 pt had received only high dose dexametazone (D); 2 pts had received autologous stem cell transplantation and 1 pt allogenic bone marrow transplantation; mean n.° of BP doses was 41.3 (17–81). At the time of ABN onset all pts were receiving ZA along with, respectively: D (2 pts); cyclophosphamide plus D (1 pt), bortezomib plus D (2 pts) and oral melphalan (1 pt). ABN was localized in 2 pts at alveolar bone of the right maxilla and presented as an inflammation of the gum, followed by a painful bone exposure. In the other 4 pts ABN was localized at mandible and presented as dental abscesses followed in 2/4 pts by cutaneous fistulization. Treatment has included in all pts discontinuation of ZA, antibiotics, chlorhexidine mouthwashes, pain control, minor regional débridement, and bone trimming. In 1 pt a more aggressive surgical approach was attempted at an other Institution and postoperative course was complicated by massive haemorrhage and complete loss of chewing. Four pts dead with progressive disease with a mean overall survival after ABN presentation of 6 mo.; 2 pts are alive after 3 and 4 mo. after ABN presentation; however in all pts ABN significantly worsened quality of life. Conclusions: Oral cavity ABN is a severe complication in refractory MM pts receiving BP. Mechanisms of action of BP that determine a reduction in osteoclastic activity and an accumulation of nonvital osteocytes with microfractures of old mineral matrix appear to play an important role. However other causes may be involved as a long history of disease; an uncontrolled progressive disease; type and doses of previous and present therapies, primarily steroids; status of oral cavity and teeth of pts and possibly the n.° of doses of BP. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
7

Tóth, András Dávid, Gergely Varga, Nikolett Wohner, et al. "Bortezomib-thalidomid-dexametazon-terápiára refrakter myeloma multiplexes esetek elemzése két budapesti centrum adatai alapján." Hematológia−Transzfuziológia 52, no. 4 (2019): 225–31. http://dx.doi.org/10.1556/2068.2019.52.4.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hardi, Apor, Gergely Varga, Zsolt Nagy, et al. "Hosszú távú progressziómentes túlélés relabált, refrakter myeloma multiplex tisztán orális ixazomib-lenalidomid-dexametazon kezelésével." Orvosi Hetilap 162, no. 36 (2021): 1451–58. http://dx.doi.org/10.1556/650.2021.32179.

Full text
Abstract:
Összefoglaló. Bevezetés: A myeloma multiplex mindmáig alapvetően gyógyíthatatlan betegség, ezért nagy klinikai jelentőségük van az eredményes mentő kezeléseknek. A szájon át adható első proteaszómagátlóval, az ixazomibbal kiegészített lenalidomid-dexametazon terápia jól tolerálható, csak orális szerekből álló kombináció, mely hazánkban 2015 áprilisától kezdődően a „Named Patient Program” keretén belül vált elérhetővé relabált, refrakter myeloma multiplexes betegek kezelésére. Célkitűzés: Kutatásunk célja az ixazomib-lenalidomid-dexametazon kezelés mellett a hosszú távon progressziómentes túlélők célzott vizsgálata. Módszer: A program keretében összesen 7 centrumban 80 visszaeső beteg részesült e triplet kezelésben, adataikat retrospektíven elemeztük. Leíró statisztikai és Kaplan–Meier-analízist végeztünk. Eredmények: A betegek nagyobb hányada reagált: 63,75%-os válaszarány mellett 14 (17,5%) betegnél nem volt terápiás válasz/stabil betegség alakult ki, és 15-nél (18,75%) a betegség a kezelés mellett is progrediált. A progressziómentes túlélés a teljes betegcsoportban 10,6 hónapnak adódott, ugyanakkor 16 beteg (18,75%) két éven túl progressziómentesnek bizonyult, sőt közülük 11-nél a betegség még 3 év után sem progrediált. Tanulmányunkban a fenti, hosszú távú túlélő betegcsoport tulajdonságait tárjuk fel. Megbeszélés: A folyamatos terápia a myeloma multiplex kezelésében meghatározóvá vált. Ezért fontos ismernünk, hogy kik lehetnek azok a betegek, akik különösen sokat profitálnak egy bizonyos terápiából. A hosszú távon progressziómentes túlélők között az immunglobulin-nehézláncot érintő transzlokációk vagy triszómiák közül (trend szintjén) az utóbbiak kedvezőbb progressziómentes túléléssel bírtak, de progressziómentes platót mindkét betegcsoportban észleltünk. A betegség tumortömegét mérő nemzetközi stádiumbeosztás (ISS) nem jelezte előre a hosszú túlélést. Gyógyszerelhagyáshoz vezető mellékhatást a hosszú távú túlélő csoportban egyet sem regisztráltunk; az észlelt mellékhatások nagy része enyhe volt. Következtetések: Munkánk során az ixazomib-lenalidomid-dexametazon kombinációt effektívnek és biztonságosnak találtuk relabált, refrakter myeloma multiplex kezelésére, mely a betegek mintegy hatodánál több éven át eredményesen alkalmazható. Cikkünkkel a hazai beteganyagon szerzett tapasztalatainkat szeretnénk megosztani a COVID–19-világjárvány alatt különösen aktuálissá vált, tisztán orális terápiás lehetőségről. Orv Hetil. 2021; 162(36): 1451–1458. Summary. Introduction: Despite great advances in therapy, multiple myeloma is still a largely incurable disease, therefore the importance of salvage therapies is paramount. The first oral proteasome inhibitor ixazomib in combination with lenalidomide-dexamethasone is a tolerable, orally administered regime, which has become available for Hungarian relapsed, refractory multiple myeloma patients from April 2015 in the Named Patient Program. Objective: Our goal was to investigate the long-time progression-free surviving patient population treated with the ixazomib-lenalidomide-dexamethasone triplet. Method: We retrospectively studied a total of 80 patients from 7 centers who received the triplet combination. Survival analyses were performed. Results: Two-third of the patients responded: the overall response rate was 63.75%. 14 patients (17.5%) did not respond/had stable disease and 15 patients (18.75%) outright progressed upon therapy. Although progression-free survival was only 10.6 months for the entire patient cohort, the disease in a subgroup of 16 patients did not progress within two years. In fact, 11 of them were still in sustained remission after 3 years of therapy. Our goal was to analyze the characteristics of this subgroup. Discussion: The idea of long-term therapy of multiple myeloma is gaining widespread acceptance. Therefore it is important to know which patients may benefit the most from certain therapies. Among these 16 long-term responder patients, reciprocal translocation of the immunoglobulin heavy chain seemed to lack an adverse impact on progression-free survival; comparable to trisomies, both curves had a progression-free plateau. The International Staging System (ISS) score at the start of therapy did not predict long-term survivorship. Most of the side effects in this subgroup were mild, manageable, none led to therapy discontinuation. Conclusion: Ixazomib-lenalidomide-dexamethasone was confirmed to be an effective and safe combination for relapsed, refractory multiple myeloma, and one-sixth of the treated patients were able to receive it for several years, effectively. This fully oral therapeutic option is at its best during the present COVID–19 pandemic. Orv Hetil. 2021; 162(36): 1451–1458.
APA, Harvard, Vancouver, ISO, and other styles
9

Melo, U. P., C. Ferreira, and M. S. Palhares. "Obstrução recorrente das vias aéreas em muares: relato de três casos." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 59, no. 3 (2007): 627–33. http://dx.doi.org/10.1590/s0102-09352007000300012.

Full text
Abstract:
Relatam-se três casos de obstrução recorrente das vias aéreas em muares com idade média de 10 anos. Os animais eram utilizados para concurso de marcha e criados em campo. Após serem mantidos em cocheiras com cama de serragem e alimentados com feno (tifton e alfafa) e ração comercial, começaram a manifestar intolerância ao exercício e episódios de tosse durante o exercício. Após exames clínico e laboratorial, instituiu-se terapia à base de clenbuterol, dexametazona e bromexina, além de controle ambiental. Após 21 dias de tratamento, ocorreu remissão dos sintomas clínicos. Para comprovação diagnóstica, os animais foram submetidos ao desafio ambiental, por um período de dois dias. Após o tratamento, os três animais voltaram a desempenhar suas atividades atléticas de modo satisfatório.
APA, Harvard, Vancouver, ISO, and other styles
10

Adam, Zdeněk, Zita Chovancová, Markéta Nová, et al. "Remission of the disease associated/related with immunoglobulin IgG4 accompanied by multiple lymphadenopathy after treatment with rituximab and dexamethasone: a case report." Vnitřní lékařství 64, no. 3 (2018): 290–99. http://dx.doi.org/10.36290/vnl.2018.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Dexametazone"

1

Odenthal, Maria Esther. "Uso da bromocriptina e da dexametasona na interrupção da gestação em cadelas." Universidade Federal de Viçosa, 2003. http://locus.ufv.br/handle/123456789/5170.

Full text
Abstract:
Made available in DSpace on 2015-03-26T13:47:20Z (GMT). No. of bitstreams: 1 texto completo.pdf: 235255 bytes, checksum: e59ffc4b4d93eb2387e5b1f9aaefaf2a (MD5) Previous issue date: 2003-12-16<br>With the goal of evaluating the efficacity of bromocriptine and dexametazone, 30 mongrel bitches, with more than 35 days of pregnancy confirmed by ultrasonography, clinicaly healthy, with weights varying between 10 and 30 kgs, were divided in three groups: Group 1 - Underwent treatment with bromocriptine for 6 days with a dosage of 0,03 mg/kg every 12 hours; Group 2 Underwent treatment with dexametasone for 10 days with a dosage of 0,2 mg/kg every 12 hours; Group 3 control. The results demonstrated that both the animals treated with bromocriptine as well as those treated with dexametasone had their pregnancies interrupted in 90% of the cases. In the conditions in which the present experiment was made, no serious endometrial alterations, with endangerment of uterine phisiology, were observed. It was verified that the abortion happens later in the group treated with dexametasone, where the phoetus expulsion may occur up to the 10th day after the treatment.<br>Objetivando avaliar o efeito abortivo de bromocriptina e da dexametasona, 30 cadelas sem raça definida, com mais de 35 dias de gestação, confirmada por ultrasonografia, clinicamente sadias, com peso variando entre 10 e 30 kg foram separadas em três grupos, a saber: Grupo 1 - Submetidas ao tratamento com bromocriptina durante 6 dias na dose de 0,01 mg/kg a cada 12 horas; Grupo 2 - Tratadas com dexametasona durante 10 dias na dose de 0,02 mg/kg a cada 12 horas; Grupo 3- Controle. Os resultados demonstraram que tanto os animais tratados com bromocriptina, como aqueles tratados com dexametasona tiveram suas gestações interrompidas em 90% dos casos. Na condição em que foi realizado o presente experimento, não foram observadas alterações endometriais graves, que pudessem comprometer a fisiologia uterina. Verificou-se que o abortamento é mais tardio no grupo tratado com dexametasona com a expulsão do feto pode ocorrer até o 10o dia após o início do tratamento.
APA, Harvard, Vancouver, ISO, and other styles
2

BOŘÍK, Adam. "Vliv environmentálních koncentrací léčiva dexametazon na ryby." Master's thesis, 2015. http://www.nusl.cz/ntk/nusl-188559.

Full text
Abstract:
Pharmaceutical pollutants have been aim of many recent aquatic environment studies. Due to human activities surface waters are polluted with plenty of substances, including products of personal care, which are ranked among a number of pharmaceuticals. The main goal of this work is to assess the impact of environmentally relevant concentrations of the synthetic glucocorticoid dexamethasone on aquatic organisms through biomarkers of oxidative stress. The principle of this experiment was chronic in vivo exposure model organisms (rainbow trout) to doses of this drug and the subsequent monitoring activities of antioxidant enzyme system in the liver and gill tissues. Experimental results have demonstrated a response enzymatic protection mechanism on the increased production of reactive oxygen species induced by the drug at environmentally relevant concentrations especially in gill tissue. Our results illustrate a real risk that this xenobiotic represents to aquatic organisms.
APA, Harvard, Vancouver, ISO, and other styles
3

Rodrigues, Liliana Patrícia Costa. "Protein oxidation and circadian rhythmicity: towards the identification of specific protein targets." Master's thesis, 2015. http://hdl.handle.net/10348/4567.

Full text
Abstract:
Dissertação de Mestrado em Bioquímica<br>O ritmo circadiano existe em todos os organismos e gera ritmos com uma periodicidade de 24 h em um significante número de processos biológicos e metabólicos. Uma disrupção do relógio circadiano (BMAL1 e PER) em ratos, está diretamente associada com o aumento das espécies reativas de oxigénio (ERO) que induzem um fenótipo de envelhecimento prematuro (Kondratov, 2007; Ramsey, et al., 2007). Por outro lado, foi descrito que a acumulação de proteínas oxidadas (carboniladas) é um marcador do envelhecimento celular. Para além disso, as proteinas carboniladas, com modificação irreversível, envolve uma diminuição da qualidade do proteoma celular que pode afectar diretamente a função da célula normal. Através da utilização de células HEK293 sincronizadas com serum shock e utilização das técnicas de electroforese de ima dimensão, o nosso grupo de trabalho demonstrou que o nível das proteínas carboniladas tinham uma ritmicidade circadiana. Essa quantificação do total de proteínas levou-nos a escolher dois picos do ritmo circadiano, correspondentes ao máximo e mínimo de nível de carbonilação. Neste trabalho, utilizamos também a electroforese de duas dimensões para caracterizar algumas proteínas em particular que pareciam sofrer oxidação circadiana. Após a quantificação das proteínas carboniladas, observou-se que os mesmos spots eram comuns em todos os tempos, mesmo se o nível de carbonilação é notavelmente diferente. Concluindo, nós provamos, embora sem proceder a uma caracterização final, que proteínas específicas possuem oxidação circadiana. No futuro, pode ser interessante identificar as proteínas alvo específicas e compará-las com os marcadores biológicos do stress oxidativo de forma a perceber melhor o envolvimento destas na ritmicidade circadiana.<br>The circadian rhythmicity exists in all organisms and generates rhythms with a periodicity of 24 h of a significant number of biological and metabolic processes. A disruption of the circadian clock (BMAL1 and PER2) in mice, are directly associated to an increase of reactive oxygen species (ROS) which induce a premature aging phenotype (Kondratov, 2007; Ramsey, et al., 2007). On the other hand, it was described that the accumulation of oxidized (carbonylated) proteins is a hallmark of cellular aging. Moreover, protein carbonylation, an irreversible modification, involves a decrease quality of the cellular proteome which could directly affect the normal cell function. Using HEK-293 cells synchronized with serum shock and the 1D electrophoresis technique, our working group showed that the level of carbonylated proteins has a circadian rhythmicity. This quantification of the total proteins allowed to choose two peaks of the circadian rhythm corresponding to maximum and minimum levels of protein carbonylation. In this work 2D electrophoresis were also used, to characterise some particular proteins, which seem to suffer a circadian oxidation. After quantification of carbonylated proteins, it was observed that the same spots are common all the times, even if their level of carbonylation is noticeably different. Concluding, it was proved, although without final characterization, that some specific proteins have a circadian oxidation. For the future, it will be interesting to identify these specific proteins and compare them to biological markers of oxidative stress in order to better understand the involvement of the circadian rhythm.
APA, Harvard, Vancouver, ISO, and other styles
4

Korbelová, Gabriela. "Koaxiální nanovlákna s inkorporovanými suplementy pro řízenou chondrogenní diferenciaci." Master's thesis, 2018. http://www.nusl.cz/ntk/nusl-388534.

Full text
Abstract:
In the field of regenerative medicine, regeneration of cartilage defects (caused either by injury or age-related degeneration, such as osteoporosis) has become a widely discussed topic. Nanofibrous scaffolds provide a suitable environment for cell adhesion, proliferation, differentiation, and also local involvement of bioactive substances. Nanofibrous scaffolds mimic the extracellular matrix (ECM) of hyaline cartilage and thus have the potential to treat cartilage defects. The aim of the work was modulation of chondrogenic differentiation medium through finding the ideal concentration of chondrogenic supplements, composed of ascorbate-2- phosphate and dexamethasone, in the culture of primary chondrocytes of pig origin seeded on a nanofibrous polycaprolactone (PCL) scaffold. The effect of different concentrations of the chondrogenic supplements on chondrocyte adhesion to the scaffold and their proliferation and differentiation was studied. Firstly, the influence of each of the supplements alone in the medium was studied, followed by study of effects of their combinations. Then, the supplements were incorporated into the nanofibers and their effect upon their release from the nanofibers was investiaged. The supplements were studied in 21-day experiments. The chondrogenic re- differentiation was best...
APA, Harvard, Vancouver, ISO, and other styles
5

Korbelová, Gabriela. "Koaxiální nanovlákna s inkorporovanými suplementy pro řízenou chondrogenní diferenciaci." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-393736.

Full text
Abstract:
In the field of regenerative medicine, regeneration of cartilage defects (caused either by injury or age-related degeneration) has become a widely discussed topic. Nanofibrous scaffolds provide a suitable environment for cell adhesion, proliferation, differentiation, and also for the local involvement of bioactive substances. Nanofibrous scaffolds mimic the extracellular matrix (ECM) of hyaline cartilage. These scaffolds are seeded with autologous chondrocytes. After having been isolated from the patient, the cells must be cultivated in vitro in order to obtain a sufficient amount of chondrocytes. Scaffolds with cultivated chondrocytes are later implanted back into the pacient. Chondrocytes, however, when grown on a 2D tissue culture plastic rapidly de-differentiate and thus lose the ability to synthesize ECM molecules. The aim of the work was modulation of chondrogenic differentiation medium through finding the ideal concentration of chondrogenic supplements, composed of L-ascorbate-2-phosphate (A2P) and dexamethasone (DEX), in the culture of primary chondrocytes seeded on a nanofibrous polycaprolactone (PCL) scaffold. The effect of different concentrations of the chondrogenic supplements on chondrocyte adhesion to the scaffold and their proliferation and differentiation was studied. The influence...
APA, Harvard, Vancouver, ISO, and other styles
6

Paušlyová, Lucia. "Synchronizace perifernich cirkadiannich hodin během ontogeneze." Master's thesis, 2013. http://www.nusl.cz/ntk/nusl-323657.

Full text
Abstract:
The circadian system is an important coordinator of physiological functions of a mammalian organism. It comprises of a central oscillator represented by cells in the suprachiasmatic nuclei of hypothalamus (SCN) and peripheral oscillators in most if not all cells of peripheral tissues. The peripheral oscillators, similarly to the central ones, generate circadian oscillations at the level of so called clock genes and their protein products. In peripheral tissues, oscillations in expression of the individual clock genes are autonomous, however, they need to be synchronized to ensure their robust rhythmic expression. The peripheral clocks are synchronized mainly by rhythmical signals from the SCN, including signals regulating food intake. Disturbances in the clock gene expressions, as well as impaired synchronization signals, can result in various pathophysiological states. Spontaneously hypertensive rat (SHR) strain is a convenient animal model to study potential connection between the disturbed circadian system and progressive development of hypertension and metabolical diseases in mammals. Various studies have shown differences in the rhythmical expression of clock genes between SHR strain and normotensive Wistar/Wistar-Kyoto strain. The aim of this thesis is to provide insight into the early...
APA, Harvard, Vancouver, ISO, and other styles
7

Krupková, Michaela. "Funkčně genomická a farmakogenomická analýza aspektů metabolického syndromu." Doctoral thesis, 2014. http://www.nusl.cz/ntk/nusl-338061.

Full text
Abstract:
Metabolic syndrome is a prevalent disease characterized by concurrent manifestation of insulin resistance, obesity, dyslipidemia, hypertension and other hemodynamic and metabolic disorders. It has multifactorial type of inheritance and its resultant phenotype is determined by both environmental and genetic factors as well as their interactions. That is the main reason why comprehensive analysis of the genetic component of this syndrome is complicated in human population. Genetically designed experimental animal models are significant tools for analysis of genetic architecture of human complex conditions including the metabolic syndrome. The aim of this Thesis is utilization of functional and comparative genomic tools to uncover pathogenesis of metabolic syndrome aspects and their genetic determinants. We also studied pharmacogenetic interactions of these genetic determinants with drugs affecting particular components of the metabolic syndrome. Establishing and utilizing several genetically designed congenic rat strains, we undertook four different research projects focusing on pharmacogenetic interaction of all-trans retinoic acid and ondansetron with differential segment of rat chromosome 8, pharmacogenetic interaction of differential segment of rat chromosome 4 and dexamethasone, determining Plzf...
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Dexametazone"

1

Sipos, Bence, Ildikó Csóka, and Gábor Katona. "Dexametazon-tartalmú polimer micellák fejlesztése és vizsgálatai „nose-tobrain” beviteli céllal Quality by Design alapon." In III. Fiatal Technológusok Fóruma. MGYT Gyógyszertechnológiai Szakosztály, 2020. http://dx.doi.org/10.14232/ftf.2020.op1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!